Otros idiomas Avenue Therapeutics, Inc.

Acciones

ATXI

US05360L4032

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
4,76 ^USD	-4,99 %		-32,70 %	-60,58 %

18/03	Avenue Therapeutics, Inc. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI
22/02	Avenue Therapeutics, Inc. Anuncia la publicación en Drug Development Research que destaca los datos preclínicos de primera clase de BAER-101 en un modelo traslacional de epilepsia de ausencia	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29/04
Avenue Therapeutics Announces Reverse Stock Split	24/04
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	25/03
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	18/03
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	15/03
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	11/03
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy	22/02
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	22/02
Certain Stock Options of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference	11/01
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds	05/01
Top Midday Gainers	04/01
Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study	04/01
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol	04/01
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	03/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Avenue Therapeutics, Inc.

Acciones

ATXI

US05360L4032

Otros idiomas

Filtros